GSK turns to Chiome for antibody discovery

GlaxoSmithKline ($GSK) has turned to Japan's Chiome Bioscience to help hunt up new antibodies to fight cancer. GSK plans to start with a pilot program to test Chiome's antibody platform. Chiome, which boasts some fast turnaround times, has also inked deals with Five Prime Therapeutics and OncoMed Pharmaceuticals. No financial details were discussed. Story